Biomedisca, Inc. is a MedTech company based in Irvine, California. Biomedisca develops Medora, an investigational chairside screening test, and OraDx AI, an AI-assisted biomedical research platform, with a shared focus on oral–systemic health.
Medora™ is Biomedisca's flagship investigational point-of-care test under development. It is designed to use a small fingerstick blood sample to provide an inflammatory-risk screening signal during a dental visit, alongside periodontal findings and medical history.
OraDx AI is a separate AI-assisted biomedical research platform for organizing and exploring clinical, periodontal, biomarker, and microbiome data.
Medora is a physical screening test; OraDx AI is a separate research platform. They share an oral–systemic health focus and have distinct purposes, workflows, and development requirements.
Medora is under development, has not been cleared or approved by the U.S. FDA, and is not currently available for clinical use or sale. OraDx AI is under development for research use. Exploratory findings and research predictions are not validated clinical diagnoses or medical advice.
Our development approach brings together scientific questions, product design, and validation requirements. Visit Science & Development for the scientific background and product limitations.
Build a healthier world by developing tools for earlier inflammatory-risk screening and biomedical research.
Make oral–systemic health information more useful for research and, as products are validated and authorized, everyday preventive care.
Advance Medora's physical test development and OraDx AI's research capabilities, with clear evidence requirements for each product.
Our current work centers on two products and the evidence needed to support their intended uses:
We welcome collaborators who can help advance Medora development and OraDx AI research. Discuss your interests through our Partnerships page.
Explore the product details, scientific context, and next steps that matter to you.